University of Surrey

Test tubes in the lab Research in the ATI Dance Research

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.

Wang, Q, Yin, H, Camelliti, P, Betts, C, Moulton, H, Lee, H, Saleh, AF, Gait, MJ and Wood, MJ (2010) In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med, 12 (4). pp. 354-364.

Full text not available from this repository.

Abstract

BACKGROUND: Targeted splice modulation of pre-mRNA transcripts by antisense oligonucleotides (AOs) can correct the function of aberrant disease-related genes. Duchenne muscular dystrophy (DMD) arises as a result of mutations that interrupt the open-reading frame in the DMD gene encoding dystrophin such that dystrophin protein is absent, leading to fatal muscle degeneration. AOs have been shown to correct this dystrophin defect via exon skipping to yield functional dystrophin protein in animal models of DMD and also in DMD patients via intramuscular administration. To advance this therapeutic method requires increased exon skipping efficiency via an optimized AO sequence, backbone chemistry and additional modifications, and the improvement of methods for evaluating AO efficacy. METHODS: In the present study, we establish the conditions for rapid in vitro AO screening in H(2)K muscle cells, in which we evaluate the exon skipping properties of a number of known and novel AO chemistries [2'-O-methyl, peptide nucleic acid, phosphorodiamidate morpholino (PMO)] and their peptide-conjugated derivatives and correlate their in vitro and in vivo exon skipping activities. RESULTS: The present study demonstrates that using AO concentrations of 300 nM with analysis at a single time-point of 24 h post-transfection allowed the effective in vitro screening of AO compounds to yield data predictive of in vivo exon skipping efficacy. Peptide-conjugated PMO AOs provided the highest in vitro activity. We also show for the first time that the feasibility of rapid AO screening extends to primary cardiomyocytes. CONCLUSIONS: In vitro screening of different AOs within the same chemical class is a reliable method for predicting the in vivo exon skipping efficiency of AOs for DMD.

Item Type: Article
Authors :
NameEmailORCID
Wang, QUNSPECIFIEDUNSPECIFIED
Yin, HUNSPECIFIEDUNSPECIFIED
Camelliti, Pp.camelliti@surrey.ac.ukUNSPECIFIED
Betts, CUNSPECIFIEDUNSPECIFIED
Moulton, HUNSPECIFIEDUNSPECIFIED
Lee, HUNSPECIFIEDUNSPECIFIED
Saleh, AFUNSPECIFIEDUNSPECIFIED
Gait, MJUNSPECIFIEDUNSPECIFIED
Wood, MJUNSPECIFIEDUNSPECIFIED
Date : April 2010
Identification Number : https://doi.org/10.1002/jgm.1446
Uncontrolled Keywords : Alternative Splicing, Animals, Base Sequence, Blotting, Western, Cells, Cultured, DNA Primers, Dystrophin, Exons, Genetic Therapy, Humans, Immunohistochemistry, In Vitro Techniques, Mice, Mice, Inbred mdx, Molecular Sequence Data, Muscular Dystrophy, Duchenne, Myocytes, Cardiac, Oligonucleotides, Antisense, RNA Precursors, Reverse Transcriptase Polymerase Chain Reaction, Transcription, Genetic, Transfection
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 10:00
Last Modified : 17 May 2017 14:46
URI: http://epubs.surrey.ac.uk/id/eprint/825963

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800